3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
19
Phase 1/2
15
Phase 1
11
Phase 3
10
Phase NA
6
Phase 2/3
4
Phase EARLY_PHASE1
1
Status
Recruiting
3
Not yet recruiting
1
Sponsor Class
OTHER
4
Study Type
Interventional
4
Sponsor
Cancer Type
Lymphoid
5
Other hematologic neoplasm
4
CNS
3
Gynecologic
2
Gastrointestinal
2
Dermatologic
2
Thoracic
1
Plasma cell
1
Myeloid
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Conditions
Leukemia, Myeloid, Acute
59
Precursor Cell Lymphoblastic Leukemia-Lymphoma
44
Leukemia
29
Hematologic Neoplasms
23
Myelodysplastic Syndromes
18
Lymphoma
16
Neoplasms
15
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
12
Lymphoma, Non-Hodgkin
9
Leukemia, Lymphocytic, Chronic, B-Cell
7
Graft vs Host Disease
7
Neoplasms by Site
6
Neoplasms by Histologic Type
6
Multiple Myeloma
6
Anemia, Refractory, with Excess of Blasts
6
Recurrence
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasms, Plasma Cell
5
Neoplasm, Residual
5
Leukemia, Biphenotypic, Acute
5
Infections
5
Primary Myelofibrosis
4
Lymphoproliferative Disorders
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large B-Cell, Diffuse
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Myeloid, Chronic-Phase
4
Leukemia, Myeloid, Accelerated Phase
4
Glioma
4
Congenital Abnormalities
4
Interventions
entrectinib
2
alectinib
2
trametinib
1
pertuzumab
1
dabrafenib
1
cobimetinib
1
capmatinib
1
atezolizumab
1
Vemurafenib
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lymphoproliferative Disorders
×
Other hematologic neoplasm
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled